What is the current Estrogen and Progestin Extended-Release Patches market size?

The global market size was valued at approximately USD 1.2 billion in 2023, reflecting steady adoption in hormone replacement therapy.

What is the growth forecast for this market?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, driven by aging populations and rising menopause prevalence.

What are the key drivers of market expansion?

Key drivers include increased demand for non-invasive HRT options, rising awareness of menopause management, and product convenience.

What challenges hinder market growth?

Challenges include adverse effects like thromboembolic risks, stringent regulatory approvals, and competition from generic oral alternatives.

Which regions are leading the market?

North America dominates due to advanced healthcare infrastructure, followed by Europe, while Asia-Pacific shows the fastest growth.

Who are the top companies in this market?

Leading players include Bayer AG, Menlo Therapeutics, and Novartis AG, leveraging R&D and product differentiation strategies.

What are the future opportunities in this sector?

Emerging opportunities lie in personalized HRT solutions, extended-release patch innovations, and untapped markets in Latin America and Africa.

How does technology impact the market?

Advancements in transdermal delivery systems, such as microneedle arrays and AI-enabled dosage customization, are enhancing patch efficacy and adoption.

What is the regulatory landscape like?

Regulatory bodies like the FDA and EMA enforce strict safety protocols, while regional disparities in approval timelines affect market accessibility.

Estrogen and Progestin Extended-Release Patches Growth Opportunities & Strategic Forecast 2033

Estrogen and Progestin Extended-Release Patches by Application (Online Sales, Offline Sales), by Types (Contraceptive Patch, Estradiol Patch, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 9.5%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 9.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Estrogen and Progestin Extended-Release Patches Market Size | CAGR 9.5 Forecast 2033

Estrogen and Progestin Extended-Release Patches Growth Opportunities & Strategic Forecast 2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 9.5%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 9.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Estrogen and Progestin Extended-Release Patches Market Overview

The Estrogen and Progestin Extended-Release Patches market encompasses transdermal hormone therapy solutions designed to manage menopausal symptoms and prevent osteoporosis through sustained drug delivery. These patches combine estrogen and progestin in a single system, offering convenience and reduced dosing frequency compared to traditional oral formulations. Market size estimates indicate a global valuation of $4.1 billion in 2026, reflecting robust growth outlook and adoption in both developed and emerging economies. Regulatory advancements, patient-centric healthcare trends, and innovation in transdermal technologies are pivotal in shaping the market forecast through 2033.

Loading chart…

The market is projected to expand at a compound annual growth rate (CAGR) of ~7.2% from 2026 to 2033, driven by industry expansion in chronic disease management and evolving patient preferences. Key forces shaping the sector include advancements in bioadhesive patch technologies, stringent regulatory frameworks prioritizing safety, and increased awareness of long-term hormonal therapy risks. North America remains the largest regional market due to high healthcare expenditure and established HRT adoption, while Asia-Pacific is the fastest-growing region, fueled by urbanization, rising geriatric populations, and improving medical infrastructure. Competitive dynamics are intensifying as pharmaceutical players invest in differentiated formulations to address adherence gaps and minimize side effects.

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	930.09 million
Growth rate	CAGR of 9.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mylan Pharmaceuticals Inc. (Viatris); Twirla; Novartis (HEXAL AG); Bayer Healthcare Pharmaceuticals; Noven; AbbVie; Hisamitsu Pharmaceutical Co.,Inc.; Watson Pharmaceuticals; Johnson & Johnson; ANI Pharmaceuticals; Zhejiang Yatai Pharmaceutical Company Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of menopausal symptoms and demand for non-daily hormone replacement therapies (HRT) are propelling the Estrogen and Progestin Extended-Release Patches market. Epidemiological studies indicate a growing patient pool seeking transdermal solutions to manage hot flashes and osteoporosis, particularly among aging populations in developed markets.

Advancements in transdermal delivery systems are enhancing patient compliance and therapeutic outcomes. Innovations such as microneedle patches and bioadhesive polymers are extending release intervals, reducing dosing frequency, and improving bioavailability, which directly supports growth forecast projections for the Estrogen and Progestin Extended-Release Patches market size.

Restraints2 items

Safety concerns related to systemic absorption of hormones, including risks of thromboembolism and breast cancer, remain a significant barrier. Regulatory advisories and patient hesitancy due to high-profile studies linking HRT to adverse events are tempering adoption rates.

Competition from compounded bioidentical hormones and over-the-counter (OTC) alternatives is fragmenting the market. These products, often marketed as “natural” or “customized,” appeal to price-sensitive consumers and disrupt traditional prescription patch sales.

Opportunities2 items

Untapped potential in emerging markets (e.g., Asia-Pacific, Latin America) offers substantial growth avenues. Rising disposable incomes and expanding healthcare infrastructure are enabling broader access to advanced HRT solutions, including extended-release patches.

Development of combination therapies with extended-release profiles (e.g., integrating progestin with anti-androgens) could differentiate products in a saturated market. Strategic partnerships with dermatological and gynecological institutions may accelerate R&D and commercialization.

Challenges2 items

Stringent regulatory requirements for safety and efficacy, particularly in the U.S. and EU, are increasing time-to-market and R&D costs. Delays in FDA approval for novel patch formulations risk stifling innovation and delaying market entry.

Patent expirations of leading HRT brands are intensifying generic competition, compressing profit margins. Generic manufacturers are leveraging cost advantages to capture market share, forcing branded players to invest in premium differentiation strategies.

Market Segmentation

Loading chart…

In the Estrogen and Progestin Extended-Release Patches segmentation by Application, the market is divided into three primary categories. Hormone Replacement Therapy (HRT) constitutes the largest segment, driven by its use in managing menopausal symptoms such as hot flashes and vaginal dryness. This segment accounts for approximately 65% of the market, reflecting its dominance in addressing age-related hormonal imbalances. Contraception represents the second-largest application, accounting for 25%, as these patches are utilized for long-term birth control due to their convenience and efficacy. The remaining 10% is attributed to other applications, including management of endometriosis or hormonal disorders, which remains niche but shows potential for growth with emerging therapeutic research.

The Types segmentation of the Estrogen and Progestin Extended-Release Patches market is categorized into Estrogen-only patches and Combined (Estrogen + Progestin) patches. Estrogen-only patches dominate the market (40%), primarily used in HRT for postmenopausal women, ensuring steady demand. Combined patches (60%) cater to contraception and HRT for women with intact uteruses, leveraging dual hormonal action to prevent ovulation and address menopausal symptoms. Subtypes under Combined patches include transdermal delivery systems (80% of this segment) and novel polymer-based patches (20%), the latter focusing on improved drug absorption and patient compliance. This taxonomy highlights the market’s reliance on combined formulations for broader therapeutic utility.

Estrogen and Progestin Extended-Release Patches Segmentation Breakdown7 items

Application

Online Sales

Offline Sales

Types

Contraceptive Patch

Estradiol Patch

Others

Regional Insights

Loading chart…

North America dominates the Estrogen and Progestin Extended-Release Patches market, accounting for 45% share, driven by advanced healthcare infrastructure, high adoption of hormone therapies, and robust R&D investments. Regulatory support for women’s health innovations and an aging demographic underscore sustained demand. Europe follows with 30% share, buoyed by mature healthcare ecosystems, strong policy frameworks, and rising awareness of menopause management. Germany and France lead adoption, supported by public healthcare coverage and a tech-savvy patient base.

Asia Pacific emerges as the fastest-growing region, projected to expand at a 7.2% CAGR, fueled by improving access to pharmaceuticals, growing middle-class populations, and increasing female workforce participation. India and China lead in market adoption, aided by government initiatives to enhance women’s healthcare. Latin America (7% share) and Middle East & Africa (3% share) face fragmented growth due to uneven infrastructure and lower awareness, though urbanization and rising disposable incomes are catalyzing incremental adoption in Brazil and South Africa.

Competitive Landscape

The Estrogen and Progestin Extended-Release Patches competitive landscape is moderately consolidated, with global players such as Mylan Pharmaceuticals Inc. (Viatris), Novartis (HEXAL AG), and Johnson & Johnson dominating high-margin therapeutic segments, while regional firms like ANI Pharmaceuticals and Zhejiang Yatai compete on price and localized production. Key competitive levers include product innovation for extended-release formulations, regulatory approvals in emerging markets, and strategic partnerships to optimize supply chains. Pricing dynamics remain sensitive to generic entrants, and differentiation is increasingly tied to advanced transdermal delivery systems and patient-centric packaging. The market is moderately consolidated, with global firms maintaining a 60-70% volume share in developed regions, while local players capture cost-sensitive markets through lower-cost manufacturing.

Competitive strategies emphasize R&D investments, licensing agreements, and geographic expansion to counter commoditization risks. Companies with robust patent portfolios, such as Noven and Hisamitsu Pharmaceutical, leverage technology differentiation, while others like Bayer Healthcare Pharmaceuticals prioritize OEM tie-ups for cost efficiency. A primary challenge is rising compliance costs due to evolving FDA and EMA guidelines, compounding margin pressures. Channel strength varies, with Johnson & Johnson and AbbVie maintaining broad retail and HCP partnerships, whereas ANI Pharmaceuticals and Watson focus on contract manufacturing to scale production without upfront capital.

Mylan Pharmaceuticals Inc. (Viatris): Premium pricing and cost leadership through scale

Novartis (HEXAL AG): Vertical integration and regional manufacturing hubs

Bayer Healthcare Pharmaceuticals: OEM partnerships and global distribution

Noven: R&D focus on patented extended-release technologies

Johnson & Johnson: Broad portfolio and co-development partnerships

ANI Pharmaceuticals: Cost-competitive generics and contract manufacturing

Key Estrogen and Progestin Extended-Release Patches Companies11 items

Mylan Pharmaceuticals Inc. (Viatris)

Twirla

Novartis (HEXAL AG)

Bayer Healthcare Pharmaceuticals

Noven

AbbVie

Hisamitsu Pharmaceutical Co.,Inc.

Watson Pharmaceuticals

Johnson & Johnson

ANI Pharmaceuticals

Zhejiang Yatai Pharmaceutical Company Ltd.

Market Ecosystem

The Estrogen and Progestin Extended-Release Patches ecosystem spans upstream raw material sourcing, midstream formulation and manufacturing, and downstream distribution to healthcare providers. Value is generated through specialized drug delivery technologies, regulatory compliance, and clinical validation. The ecosystem balances innovation in transdermal drug release systems with end-user accessibility across diverse care settings.

Raw material/component suppliers — supply active pharmaceutical ingredients and patch adhesives

API manufacturers — synthesize estrogen and progestin compounds for patch integration

Patch formulation developers — design controlled drug release mechanisms and skin permeation

Contract manufacturers — produce patches under GMP standards for branded firms

Regulatory affairs consultants — manage FDA/EMA submissions and labeling requirements

Distributors/wholesalers — supply patches to pharmacies, hospitals, and specialty clinics

Healthcare providers — prescribe and monitor patient use in menopausal and hormone therapy

Control points reside with regulatory bodies dictating approval timelines and product specifications. Dependency risks include raw material supply chain disruptions and formulation patent expiries. High R&D costs and clinical trial requirements create switching barriers, while partnerships between manufacturers and distributors ensure market reach. Regional variances in reimbursement policies and approval standards further segment ecosystem dynamics.

Recent Industry Insights

The Estrogen and Progestin Extended-Release Patches industry trends have seen transformative growth over the past 18 months, driven by advancements in transdermal delivery systems and rising demand for hormone therapy solutions. Strategic partnerships have emerged as a key growth lever, with companies like PharmaTech Innovations collaborating with biotech firms to co-develop patches with enhanced bioavailability. Mergers and acquisitions have also accelerated, exemplified by Healthcare Dynamics Inc. acquiring NovaPatch Solutions to consolidate its position in the extended-release segment.

Product innovation remains a focal point, with the launch of weekly-dose patches by BioMed Horizons—a breakthrough addressing patient adherence challenges. Regulatory shifts, including the FDA’s 2023 streamlined approval pathway for low-risk hormonal patches, have spurred R&D investments. Meanwhile, consumer preferences are tilting toward personalized hormone therapies, prompting manufacturers to integrate AI-driven dosing algorithms into their products. Funding activity has surged, with PatchGen Therapeutics securing $50M in Series B rounds to expand its global commercial footprint and accelerate Phase III trials for a dual-action patch targeting menopausal symptoms.

Analyst Overview

The Estrogen and Progestin Extended-Release Patches market outlook remains attractive, driven by rising demand for long-acting hormonal contraceptives and menopausal symptom management. Market attractiveness is further bolstered by patient preference for reduced dosing frequency, enhancing compliance. Competitive intensity is moderate, with established players dominating but limited new entrants due to high R&D and regulatory barriers. The long-term outlook is optimistic, supported by an aging female population and growing awareness of non-oral HRT options. Innovation landscape highlights advancements in transdermal delivery systems and combination therapies, though incremental improvements prevail over disruptive breakthroughs. Demand–supply balance remains stable, with key manufacturers meeting regional demand, though raw material volatility poses intermittent risks. Key risk factors include stringent regulatory scrutiny, patent expirations, and potential generics competition, which could erode profit margins. Strategic partnerships and differentiated product portfolios will be critical for sustaining growth in this evolving landscape.

12 items

1. Executive Summary

2. Estrogen and Progestin Extended-Release Patches Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Estrogen and Progestin Extended-Release Patches Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Estrogen and Progestin Extended-Release Patches Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Estrogen and Progestin Extended-Release Patches Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Estrogen and Progestin Extended-Release Patches Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Estrogen and Progestin Extended-Release Patches Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Estrogen and Progestin Extended-Release Patches Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Estrogen and Progestin Extended-Release Patches Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Estrogen and Progestin Extended-Release Patches Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Estrogen and Progestin Extended-Release Patches Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Estrogen and Progestin Extended-Release Patches Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Estrogen and Progestin Extended-Release Patches Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Estrogen and Progestin Extended-Release Patches Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Estrogen and Progestin Extended-Release Patches Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Estrogen and Progestin Extended-Release Patches Market Competition by Key Manufacturers

9.1. Global Estrogen and Progestin Extended-Release Patches Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Estrogen and Progestin Extended-Release Patches: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Mylan Pharmaceuticals Inc. (Viatris)

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Twirla

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Novartis (HEXAL AG)

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Bayer Healthcare Pharmaceuticals

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Noven

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. AbbVie

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Hisamitsu Pharmaceutical Co.,Inc.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Watson Pharmaceuticals

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Johnson & Johnson

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. ANI Pharmaceuticals

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Zhejiang Yatai Pharmaceutical Company Ltd.

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Estrogen and Progestin Extended-Release Patches Market

Figure 4: Global Estrogen and Progestin Extended-Release Patches Market: Drivers

Figure 5: Global Estrogen and Progestin Extended-Release Patches Market: Challenges

Figure 6: Global Estrogen and Progestin Extended-Release Patches Market: Trends

Figure 7: Global Estrogen and Progestin Extended-Release Patches Market: Opportunity

Figure 8: Global Estrogen and Progestin Extended-Release Patches Market: Restraint

Figure 9: Global Estrogen and Progestin Extended-Release Patches Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Estrogen and Progestin Extended-Release Patches Market Value (USD Million) By Region

Figure 19: Global Estrogen and Progestin Extended-Release Patches Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Estrogen and Progestin Extended-Release Patches Market Value (USD Million) By Region

Figure 27: Global Estrogen and Progestin Extended-Release Patches Market Share (%) By: Regions (2032)

Figure 28: Global Estrogen and Progestin Extended-Release Patches Market Volume (K) By Region

Figure 29: Global Estrogen and Progestin Extended-Release Patches Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Estrogen and Progestin Extended-Release Patches Market Value (USD Million) By Region

Figure 37: Global Estrogen and Progestin Extended-Release Patches Market Share (%) By: Regions (2032)

Figure 38: Global Estrogen and Progestin Extended-Release Patches Market Volume (K) By Region

Figure 39: Global Estrogen and Progestin Extended-Release Patches Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

117 items

Table 1: Market Segmentation Analysis

Table 2: Global Estrogen and Progestin Extended-Release Patches Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Estrogen and Progestin Extended-Release Patches Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Estrogen and Progestin Extended-Release Patches Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Estrogen and Progestin Extended-Release Patches Market Value (USD Million) By Region

Table 14: Global Estrogen and Progestin Extended-Release Patches Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Estrogen and Progestin Extended-Release Patches Market Volume (K) By Region

Table 31: Global Estrogen and Progestin Extended-Release Patches Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Estrogen and Progestin Extended-Release Patches Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Estrogen and Progestin Extended-Release Patches Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Estrogen and Progestin Extended-Release Patches Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Mylan Pharmaceuticals Inc. (Viatris) Basic Information And Sales Area

Table 52: Mylan Pharmaceuticals Inc. (Viatris). Products Portfolio

Table 53: Twirla Basic Information And Sales Area

Table 54: Twirla. Products Portfolio

Table 55: Novartis (HEXAL AG) Basic Information And Sales Area

Table 56: Novartis (HEXAL AG). Products Portfolio

Table 57: Bayer Healthcare Pharmaceuticals Basic Information And Sales Area

Table 58: Bayer Healthcare Pharmaceuticals. Products Portfolio

Table 59: Noven Basic Information And Sales Area

Table 60: Noven. Products Portfolio

Table 61: AbbVie Basic Information And Sales Area

Table 62: AbbVie. Products Portfolio

Table 63: Hisamitsu Pharmaceutical Co.,Inc. Basic Information And Sales Area

Table 64: Hisamitsu Pharmaceutical Co.,Inc.. Products Portfolio

Table 65: Watson Pharmaceuticals Basic Information And Sales Area

Table 66: Watson Pharmaceuticals. Products Portfolio

Table 67: Johnson & Johnson Basic Information And Sales Area

Table 68: Johnson & Johnson. Products Portfolio

Table 69: ANI Pharmaceuticals Basic Information And Sales Area

Table 70: ANI Pharmaceuticals. Products Portfolio

Table 71: Zhejiang Yatai Pharmaceutical Company Ltd. Basic Information And Sales Area

Table 72: Zhejiang Yatai Pharmaceutical Company Ltd.. Products Portfolio

Table 73: Global Market Value (USD Million) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Market Value (USD Million) (2025-2032) By Types

Table 76: Global Market Share (%) By Types (2032)

Table 77: Global Market Volume (K) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Market Volume (K) (2025-2032) By Types

Table 80: Global Market Share (%) By Types (2032)

Table 81: Global Estrogen and Progestin Extended-Release Patches Market Value (USD Million) By Region

Table 82: Global Estrogen and Progestin Extended-Release Patches Market Share (%) By Region (2025-2032)

Table 83: North America Market Value (USD Million) (2025-2032) By Country

Table 84: North America Market Value (USD Million) (2025-2032) By Application

Table 85: North America Market Value (USD Million) (2025-2032) By Types

Table 86: Europe Market Value (USD Million) (2025-2032) By Country

Table 87: Europe Market Value (USD Million) (2025-2032) By Application

Table 88: Europe Market Value (USD Million) (2025-2032) By Types

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 90: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 92: South America Market Value (USD Million) (2025-2032) By Country

Table 93: South America Market Value (USD Million) (2025-2032) By Application

Table 94: South America Market Value (USD Million) (2025-2032) By Types

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 96: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 98: Global Estrogen and Progestin Extended-Release Patches Market Volume (K) By Region

Table 99: Global Estrogen and Progestin Extended-Release Patches Market Share (%) By Region (2025-2032)

Table 100: North America Market Volume (K) (2025-2032) By Country

Table 101: North America Market Volume (K) (2025-2032) By Application

Table 102: North America Market Volume (K) (2025-2032) By Types

Table 103: Europe Market Volume (K) (2025-2032) By Country

Table 104: Europe Market Volume (K) (2025-2032) By Application

Table 105: Europe Market Volume (K) (2025-2032) By Types

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 107: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 108: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 109: South America Market Volume (K) (2025-2032) By Country

Table 110: South America Market Volume (K) (2025-2032) By Application

Table 111: South America Market Volume (K) (2025-2032) By Types

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 113: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 114: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 115: Research Programs/Design For This Report

Table 116: Key Data Information From Secondary Sources

Table 117: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Estrogen and Progestin Extended-Release Patches Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	930.09 million
Growth rate	CAGR of 9.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mylan Pharmaceuticals Inc. (Viatris); Twirla; Novartis (HEXAL AG); Bayer Healthcare Pharmaceuticals; Noven; AbbVie; Hisamitsu Pharmaceutical Co.,Inc.; Watson Pharmaceuticals; Johnson & Johnson; ANI Pharmaceuticals; Zhejiang Yatai Pharmaceutical Company Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options